RVMD — Revolution Medicines, Inc.
Is RVMD overbought or oversold? Here is the current MarketMoodz read.
Revolution Medicines, Inc. (RVMD) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $166.87. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$166.87
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Revolution Medicines, Inc. (RVMD) is a pipeline-centric oncology company with differentiated targeted therapy programs that can deliver significant upside if clinical data are positive and partnerships materialize. The company benefits from platform-level intellectual property and potential strategic interest from larger pharma, but near-term performance is constrained by binary clinical risk, uncertain financing needs (no recent EDGAR comparison in the provided data), and a cautious market tone that favors defensive large-cap healthcare. Key catalysts include upcoming trial readouts and any announced collaborations; adverse outcomes or financing pressure are the principal downside scenarios.
Key factors
- Pipeline driven business model with novel targeted oncology programs that can generate binary, high-impact clinical readouts
- Platform differentiation around targeted small molecules (RAS pathway focus) that could offer durable competitive advantage if clinical efficacy/safety proven
- Potential for strategic partnerships or M&A interest from large-cap pharma given sector appetite for specialty oncology assets
- Current market backdrop is cautious and defensive, reducing near-term upside from broad market flows
- Limited company-specific public filing comparison available in the provided data set, increasing uncertainty about exact financial runway and near-term guidance
- Biotech valuations remain sensitive to trial readouts and macro liquidity; positive readouts could materially re-rate the equity
Risks
- Clinical trial failure or disappointing efficacy/safety data for lead programs, causing large share price declines
- Unclear cash runway or need for dilutive financing if operating burn exceeds expectations and partnerships are not secured
- Regulatory setbacks or slower-than-expected approval timelines for oncology indications
- Competition from larger pharma/biotech with deeper portfolios and faster commercialization capabilities
- Market risk: defensive investor flows and macro uncertainty could compress valuation multiple before catalysts materialize
- Lack of social sentiment and limited near-term public disclosures in the provided dataset increases information asymmetry for investors
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for RVMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.